Is running associated with a lower risk of all-cause, cardiovascular and cancer mortality, and is the more the better? A systematic review and meta-analysis. Issue 15 (4th November 2019)

• Record Type: Journal Article
• Authors: Pedisic, Zeljko; Shrestha, Nipun; Kovalchik, Stephanie; Stamatakis, Emmanuel; Liangruenrom, Nucharapon; Grgic, Jozo; Titze, Sylvia; Biddle, Stuart JH; Bauman, Adrian E; Oja, Pekka
• Is Part Of: British journal of sports medicine. Volume 54:Issue 15(2020)
• Page Start: 898
• Page End: 905
• Publication Date: 2019-11-04
• Subjects: exercise -- physical activity -- running -- sport -- survival; Sports medicine -- Periodicals; 617.1027
• DOI: 10.1136/bjsports-2018-100493
• Languages: English
• ISSNs: 0306-3674

Abstract

Abstract : Objective: To investigate the association of running participation and the dose of running with the risk of all-cause, cardiovascular and cancer mortality. Design: Systematic review and meta-analysis. Data sources: Journal articles, conference papers and doctoral theses indexed in Academic Search Ultimate, CINAHL, Health Source: Nursing/Academic Edition, MasterFILE Complete, Networked Digital Library of Theses and Dissertations, Open Access Theses and Dissertations, PsycINFO, PubMed/MEDLINE, Scopus, SPORTDiscus and Web of Science. Eligibility criteria for selecting studies: Prospective cohort studies on the association between running or jogging participation and the risk of all-cause, cardiovascular and/or cancer mortality in a non-clinical population of adults were included. Results: Fourteen studies from six prospective cohorts with a pooled sample of 232 149 participants were included. In total, 25 951 deaths were recorded during 5.5–35 year follow-ups. Our meta-analysis showed that running participation is associated with 27%, 30% and 23% lower risk of all-cause (pooled adjusted hazard ratio (HR)=0.73; 95% confidence interval (CI) 0.68 to 0.79), cardiovascular (HR=0.70; 95% CI 0.49 to 0.98) and cancer (HR=0.77; 95% CI 0.68 to 0.87) mortality, respectively, compared with no running. A meta-regression analysis showed no significant dose–response trends for weekly frequency, weekly duration, pace and the total volume of running. Conclusion: Increased rates of participation in running, regardless of its dose, would probably lead to substantial improvements in population health and longevity. Any amount of running, even just once a week, is better than no running, but higher doses of running may not necessarily be associated with greater mortality benefits.